PARP1 and cancer: In this study, two different transgenic Drosophila AD models were employed to evaluate the potential therapeutic effects of PARP inhibitors: olaparib [64], already approved for the treatment of several cancer types (for a review see [65]) and MC2050, a new inhibitor, previously developed by our team, that has been shown to have neuroprotective effects in cellular models of Aβ peptides-induced neurotoxicity [35,66].